Celldex receives Breakthrough Therapy Designation

The Food and Drug Administration granted Breakthrough Therapy Designation to Celldex Therapeutics Inc.'s (Nasdaq: CLDX) adult patients with EGFRvIII-positive glioblastoma treatment rindopepimut. Shares of the biopharmaceutical leaped $3.52 to close at $24.73.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.